Trelagliptin Succinate CAS NO.1029877-94-8

1. Trelagliptin Information

Specification: In-house
 

Status: Pilot

Best Service, High Quality and Reasonable Price. More information, please contact us.

2. Easton Introduction

Chengdu Easton Biopharmaceuticals Co., Ltd., built in accordance with EU and US GMP standards, is a High-Tech company specialized in development, manufacture and distribution of drug substances and drug products.
 

3. Easton Quality System
 

3.1 Quality Team

Easton has about 50 professional staff in quality system, including quality assurance, quality control and quality research. The system is led by GMP experts and technical experts who have extensive GMP certification experience,to ensure our products and overall management system can continuously meet the cGMP requirements and also international regulatory requirements.

3.2 Authority Inspections

2009~2012  Totally 7 APIs approved by CFDA.

2010~2013  Formulation line for Tablets, Capsule,Injection solution and Vials approved by CFDA.

2014~2015  10 APIs of Qingmu site inspected and approved by CFDA.

4. Easton R&D System

4.1 R&D Team
 

Internal experts: PHDs and senior scientists, totally about 100.

Outside supporting: Universities, Institutes and CRO companies
 

4.2 Advanced Instruments

LC-MS, Atomic Absorption Spectrometer, etc.

4.3 Main R&D Directions

New Molecule Entity

New Indication of Exist Drugs

Innovation Generics: extended release, new dosage form, etc
 

4.4 R&D Strategy
 

1. Easton Introduction

Chengdu Easton Biopharmaceuticals Co., Ltd., built in accordance with EU and US GMP standard, is a High-Tech company specialized in development, manufacture and distribution of drug substances and drug products.
 

Established: 2009      

Located: Chengdu City  
 

Main Business

APIs, Finished Dosage Forms and CMO
 

Main Markets

China, EU, North America (US and Canada), Japan and other non-regulatory markets
 

Easton Vision

Responsible pharmaceutical company for patients

Reliable international partner on both FDF and APIs
 

Easton Philosophy

Sunshine, Value, Innovation and Efficiency

2. API Manufacture Site-Sichuan Qingmu 
 

Established in 2011, Sichuan Qingmu Pharmaceutical Co., Ltd. is a full subsidiary of Easton Biopharma, mainly produces and provides high quality APIs and advanced pharmaceutical intermediates for global customers.
 

Located in Sichuan Meishan, the new facility is designed by world famous engineering company as the US and EU GMP standards and EHS requirements, total area is 71,200m² and overall capacity is about 200mt/year.Investment of phase-I facility reached up to 160 million RMB, the production line of APIs was completed at the end of 2013 and commercial activity started from Q3 2014.
 

Currently, 10 APIs of this manufacturing site had been approved by CFDA and GMP certificates had been issued.
 

Located: Meishan, Sichuan 
 

Total Area: 71,200m²     
 

Capacity: 200mt/year 
 

Capability

Hydrogenation Reaction
 

Pinner Reaction

Grignard Reaction

Temperature Range: -80℃~150℃

Pressure Range: 0~40MPa
 

Reactor Volume: 50~3000L
 

API Plant

Lab